Latest Healthcare Policy news from across the web.
“Innovations like xenotransplantation would never have reached clinical trials without animal experimentation,” writes transplant surgeon Joshua Mezrich.
Read full article →GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
Read full article →A government-commissioned study had been meant to inform new dietary guidelines, and found risks associated with even light drinking.
Read full article →Due to advancements in treatment and screening, more Americans are surviving cancer. But many are left with lingering mental health challenges like anxiety and depression.
Read full article →Recent studies suggest GLP-1s, the weight loss and diabetes drugs, may both prevent cancer and slow its progression. While weight loss is known to curb cancer risks, GLP-1s may act on other brain and metabolic pathways to prevent cancer.
Read full article →Health workers at the epicenter of Congo's Ebola outbreak are laboring with little pay or rest.
Read full article →AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
Read full article →The Democratic Republic of Congo's Ebola outbreak is spreading at an unprecedented pace, Africa CDC warns.
Read full article →The biggest U.S. health insurer is changing how it pays for lactation counseling, and it could cut payment for many providers.
Read full article →Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news
Read full article →Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide
Read full article →Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.
Read full article →